We claim:

1

2

4

1. A compound of the Formula

and their pharmaceutically acceptable salts, wherein

R', R' are independently of each other

5 (i) a C<sub>1-2</sub> arkyl, straight chain or branched-chain, optionally mono- or

6 polysubstituted by -OH, -SH, -NH2, -NHC1-6 alkyl, -N(C1-6 alkyl)2, -NHC6-14

7 aryl,  $-N(C_{6-14} \text{ aryl})_2$ ,  $-N(C_{1-6} \text{ arkyl})(C_{6-14} \text{ aryl})$ ,  $NHCOR^6$ ,  $-NO_2$ , -CN, -F, -Cl,

8 -Br, -I, -O-C<sub>1-6</sub> alkyl, -O-C<sub>6-1</sub> aryl, -O(CO)R<sup>6</sup>/-S-C<sub>1-6</sub> alkyl, -S-C<sub>6-14</sub> aryl, -SOR<sup>6</sup>,

9 -SO<sub>3</sub>H, -SO<sub>2</sub>R<sup>6</sup>, -OSO<sub>2</sub>C<sub>1-6</sub> alkyl, -OSO<sub>2</sub>C<sub>6-14</sub> aryl, -(CS)R<sup>6</sup>, -COOH, -(CO)R<sup>6</sup>,

10 mono-, bi- or tricyclic saturated or mono- or polyunsaturated carbocycles

11 having from 3 to 14 ring members, mono-, bi- or tricyclic saturated or mono-

12 or polyunsaturated heterocycles having from 5 to 15 ring members and from 1

13 to 6 heteroatoms, which are suitably N, O and S, where the C, aryl groups

14 and the included carbocyclic and heterocyclic substituents can optionally be

15 mono- or polysubstituted by R4,

16 (ii) -C<sub>2-12</sub> alkenyl, mono- or polyunsaturated, straight-chain or branched-

17 chain, optionally mono- or polysubstituted by -OH, -SH, -NH<sub>2</sub>, -NHC<sub>1-6</sub> alkyl,

18  $-N(C_{1-6} \text{ alkyl})_2$ ,  $-NHC_{6-14} \text{ aryl}$ ,  $-N(C_{6-14} \text{ aryl})_2$ ,  $-N(C_{1-6} \text{ alkyl})(C_{6-14} \text{ aryl})$ ,

19 -NHCOR<sup>6</sup>, -NO<sub>2</sub>, -CN, -F, -Cl, -Br, -I, -O-C<sub>1-6</sub> alkyl, -O-C<sub>6-14</sub> aryl, -O(CO)R<sup>6</sup>,

20 -S-C<sub>1-6</sub> alkyl, -S-C<sub>6-14</sub> aryl, -SOR<sup>6</sup>, -S\03H, -SO<sub>2</sub>R<sup>6</sup>, -OSO<sub>2</sub>C<sub>1-6</sub> alkyl, -OSO<sub>2</sub>C<sub>6-14</sub>

21 aryl, -(CS)R6, -COOH, -(CO)R6, mono-, bi- or tricyclic saturated or mono- or

22 polyunsaturated carbocycles having from 3 to 14 ring members, mono-, bi- or

```
tricyclic saturated or mono- or polyunsaturated heterocycles having from 5 to
   23
         15 ring members and from 1 to 6 heteroatoms, which are suitably N, O and
   24
         S, where the C_{6.14} aryl groups and the included carbocyclic and heterocyclic
   25
         substituents for their part can optionally be mono- or polysubstituted by R<sup>4</sup>,
   26
   27
                 (iii) mono-, bi- of tricyclic saturated or mono- or polyunsaturated
         carbocycles having from 3 to 14 ring members, optionally mono- or
   28
   29
         polysubstituted by -OH, -SH, -NH<sub>2</sub>, -NHC<sub>1-6</sub> alkyl, -N(C<sub>1-6</sub> alkyl)<sub>2</sub>, -NHC<sub>6-14</sub>
        aryl, -N(C_{6-14} \text{ aryl})_2, -N(C_{1-6} \text{ alkyl})(C_{6-14} \text{ aryl}), -NHCOR^6, -NO_2, -CN, -F, -Cl,
   30
        -Br, -I, -O-C_{I-6} alkyl, -O-C_{6-I4} aryl, -O(CO)R^6, -S-C_{I-6} alkyl, -S-C_{6-I4} aryl, -SOR^6,
<sub>|=|</sub>31
32
33
33
        -SO_3H, -SO_2R^6, -OSO_2C_{1-6} alkyl, -OSO_2C_{6-14} aryl, -(CS)R^6, -COOH, -(CO)R^6,
        mono-, bi- or tricyclic saturated or mono-/or polyunsaturated carbocycles
34
35
        having from 3 to 14 ring members, mono-, bi- or tricyclic saturated or mono-
        or polyunsaturated heterocycles having from 5 to 15 ring members and from 1
36
        to 6 heteroatoms, which are suitably N, O and S, where the C_{6-14} aryl groups
37
        and the included carbocyclic and heterocyclic substituents can optionally be
38
        mono- or polysubstituted by R4,
                (iv) mono-, bi- or tricyclic saturated or mono- or polyunsaturated
   40
        heterocycles having from 5 to 15 ring members and from 1 to 6 heteroatoms,
   41
        which are suitably N, O and S, optionally mono- or polysubstituted by -OH,
        -SH, -NH<sub>2</sub>, -NHC<sub>1-6</sub> alkyl, -N(C_{1-6} alkyl)<sub>2</sub>, -NHC<sub>6-14</sub> aryl, -N(C_{6-14} aryl)<sub>2</sub>, -N(C_{1-6}
   42
        alkyl)(C<sub>6-14</sub> aryl), -NHCOR<sup>6</sup>, -NO<sub>2</sub>, -CN, -F, -Cl, -Br, -I, -O-C<sub>1-6</sub> alkyl, -O-C<sub>6-14</sub>
   43
        aryl, -O(CO)R^6, -S-C_{1-6} alkyl, {}^1_1S-C_{6-14} aryl, -SOR^6, -SO_3H, -SO_2R^6, -OSO_2C_{1-6}
   44
        alkyl, -OSO<sub>2</sub>C<sub>6-14</sub> aryl, -(CS)R<sup>6</sup>, -COOH, -(CO)R<sup>6</sup>, mono-, bi- or tricyclic
   45
  46
        saturated or mono- or polyunsaturated carbocycles having from 3 to 14 ring
  47
        members, mono-, bi- or tricyclic saturated or mono- or polyunsaturated
  48
        heterocycles having from 5 to 15 ring members and from 1 to 6 heteroatoms,
  49
        which are suitably N, O and S, where the C_{6-14} aryl groups and the included
  50
        carbocyclic and heterocyclic substituents for their part can be optionally
```

mono- or polysubstituted by R4, -carbo- or heterocyclic saturated or mono- or

- 52 polyunsaturated spirocycles having from 3 to 10 ring members, where
- 53 heterocyclic systems contains from 1 to 6 heteroatoms, which are suitably N,
- O and S, optionally mono or polysubstituted by -OH, -SH, -NH<sub>2</sub>, -NHC<sub>1-6</sub>
- 55 alkyl,  $-N(C_{1-6} \text{ alkyl})_2$ ,  $-NHC_{6-14} \text{ aryl}$ ,  $-N(C_{6-14} \text{ aryl})_2$ ,  $-N(C_{1-6} \text{ alkyl})(C_{6-14} \text{ aryl})$ ,
- 56 -NHCOR<sup>6</sup>, -NO<sub>2</sub>, -CN, -F, Cl, -Br, -I, -O-C<sub>1-6</sub> alkyl, -O-C<sub>6-14</sub> aryl, -O(CO)R<sup>6</sup>,
- 57 -S-C<sub>1-6</sub> alkyl, -S-C<sub>6-14</sub> aryl, -SOR<sup>6</sup>, -SO3H, -SO<sub>2</sub>R<sup>6</sup>, -OSO<sub>2</sub>C<sub>1-6</sub> alkyl, -OSO<sub>2</sub>C<sub>6-14</sub>
- 58 aryl, -(CS)R6, -COOH, -(CO)R6, mono-, bi- or tricyclic saturated or mono- or
- 59 polyunsaturated carbocycles having from 3 to 14 ring members, mono-, bi- or
- 60 tricyclic saturated or mono- or polyunsaturated heterocycles having from 5 to
- 61 15 ring members and from 1-to-6-heteroatoms, which are suitably N, O and
- 62 S, where the C<sub>6-14</sub> aryl groups and the included carbocyclic and heterocyclic
- 63 substituents can optionally be mono- or polysubstituted by R4,
- 64 R<sup>2</sup>, R<sup>3</sup> are hydrogen or -OH, where at least one of the two substituents must
- 65 be -OH;
- 66 R<sup>4</sup> is -H, -OH, -SH, -NH<sub>2</sub>, -NHC<sub>1-6</sub> alkyl, -N(C<sub>1-6</sub> alkyl)<sub>2</sub>, -NHC<sub>6-14</sub> aryl,
- 67 -N( $C_{6-14}$  aryl)<sub>2</sub>, -N( $C_{1-6}$  alkyl)( $C_{6-13}$  aryl), -NHCOR<sup>6</sup>, -NO<sub>2</sub>, -CN, -COOH,
- 68 -(CO)R<sup>6</sup>, -(CS)R<sup>6</sup>, -F, -Cl, -Br, -I, -O-C<sub>1-6</sub> alkyl, -O-C<sub>6-14</sub> aryl, -O(CO)R<sup>6</sup>,
- 69 -S-C<sub>1-6</sub> alkyl, -S-C<sub>6-14</sub> aryl, -SOR<sup>6</sup>, -SO<sub>2</sub>R<sup>6</sup>.
- 70 R<sup>6</sup> is -H, -NH<sub>2</sub>, -NHC<sub>1-6</sub> alkyl, -N( $C_{1-6}$  alkyl)<sub>2</sub>, -NHC<sub>6-14</sub> aryl, -N( $C_{6-14}$  aryl)<sub>2</sub>,
- 71 -N( $C_{I-6}$  alkyl)( $C_{6-I4}$  aryl), -O- $C_{I-6}$  alkyl, -O- $C_{6-I4}$  aryl, -S- $C_{I-6}$  alkyl, -S- $C_{6-I4}$  aryl,
- 72 -C<sub>1-12</sub> alkyl, straight-chain or branched-chain, -C<sub>2-12</sub> alkenyl, mono- or
- 73 polyunsaturated, straight-chain or branched-chain, -mono-, bi- or tricyclic
- 74 saturated or mono- or polyunsaturated carbocycles having from 3 to 14 ring
- 75 members, -mono-, bi- or tricyclic saturated or mono- or polyunsaturated
- 76 heterocycles having from 5 to 15 ring members and from 1 to 6 heteroatoms,
- 77 which are suitably N, O and S;
- 78 A is either a bond, or  $-CH2)_{m}$ ,  $-(CH2)_{m}$ ,  $-(CH=CH)_{n}$ ,  $-(CH_{2})_{p}$ ,  $-(CHOZ)_{m}$ ,
- 79 -(C=O)-, -(C=S)-, -(C=N-Z)-, -O-, -S-,\-NZ-, where m and p are cardinal
- 80 numbers from 0 to 3 and n is a cardinal number from 0 to 2,

- is H, or a  $C_{1-12}$  alkyl, straight-chain or branched-chain,  $C_{2-12}$  alkenyl, 81 mono- or polyunsaturated, straight-chain or branched-chain, mono-, bi- or 82 tricyclic saturated or mono- or polyunsaturated carbocycles having from 3 to 83 14 ring members, mono-, bi- or tricyclic saturated or mono- or polyun-84 saturated heterocycles having from 5 to 15 ring members and from 1 to 6 85 heteroatoms, which are suitably N, O and S; 86 is either carbon or sulfur, or -(S=O)-; 87 В is oxygen, sulfur, CH2 or N-Z, where D can only be S or CH2 if B is 88 89 carbon; is a bond, or  $(CH2)_m$ -, -O-, -S-, -(N-Z)-, where m and Z have the same = 90 □ 91 meanings as above.
  - 2. The compound of claim 1, wherein the compound is a pharmaceutically acceptable salt of an organic or inorganic acid, or of an organic or inorganic base, or a quaternary ammonium salt from the quaternization of a tertiary amine.

2

3

- 3. The compound of claim 1, having an asymetric carbon atom by being the L or the D form, or a D,L mixture, and when in a diastereoisomeric form.
- 4. A compound of claim 1, being one of the following compounds:
  N-(3,5-dichloropyridin-4-yl)-2-[1-(4-fluorobenzyl)-5-hydroxyindol-3-yl]-2oxoacetamide;
- 4 N-(3,5-dichloropyridin-4-yl)-2-[1-(4-fluorobenzyl)-5-hydroxyindol-3-yl]-2-5 oxoacetamide Na salt;
- N-(3,5-dichloropyridin-4-yl)-2-[1-(4-fluorobenzyl)-5-hydroxyindol-3-yl]-2hydroxyacetamide;

```
N-(pyridin-4-yl)-2-[1-2,6-difluorobenzyl)-5-hydroxyindol-3-yl]-2-
     8
         oxyacetamide;
     9
                N-(3,5-dichloropyridin-4-yl)-2-[1-(2,6-difluorobenzyl)-5-hydroxyindol-3-
    10 .
         yl]-2-oxoacetamide;
    11
                N-(3,5-dichloropyridin-4-yl)-2-[1-(3-nitrobenzyl)-5-hydroxyindol-3-yl]-2-
    12
         oxoacetamide Na salt;
    13
                N-(3,5-dichloropyridin-4-yl)-2-(1-propyl-5-hydroxyindol-3-yl)-2-
    14
    15
         oxyacetamide;
                N-(3,5-dichloropyridin-4-yl)-2-(1-isopropyl-5-hydroxyindol-3-yl)-2-
    16
         oxoacetamide;
   17
                N-(3,5-dichlocopyridin-4-yl) 2-(1-cyclopentylmethyl-5-hydroxyindol-3-yl)-
   18
   19
         2-oxoacetamide;
                N-(2,6-dichloropheriyl)-2-[1-(4-fluorobenzyl)-5-hydroxyindol-3-yl]-2-
   20
   21
         oxoacetamide;
                N-(2,6-dichloro-4-trifluoromethylphenyl)-2-[1-(4-fluorobenzyl)-5-
   22
         hydroxyindol-3-yl) 2-oxoacetamide;
   23
                N-(2,6-dichloro-4-trifluoromethoxylphenyl)-2-[1-(4-fluorobenzyl)-5-
   24
25
         hydroxyindol-3-yl)-2-oxoacetamide;
                N-(3,5-dichloropyridin-4-yl)-2-[1-(4-fluorobenzyl)-6-hydroxyindol-3-yl]-2-
   26
   27
         oxoacetamide;
                N-(3,5-dichloropyridin-4\frac{1}{1}yl)-5-hydroxy-1-(4-methoxybenzyl)indole-3-
   28
   29
         carboxamide.
                    5. A process for preparing compounds of claim 1, which comprises
    1
        converting a compound of claim 1 wherein R, or R<sup>3</sup>, or R<sup>2</sup> and R<sup>3</sup> is -O-R<sup>7</sup> in
    3
        which R<sup>7</sup> is a leaving group.
                     6. The process of claim 5, wherein said leaving group is alkyl,
    1
```

cycloalkyl, arylalkyl, aryl, heteroaryl, acyl, alkoxycarbonyl, aryloxycarbonyl,

- aminocarbonyl, N-substituted aminocarbonyl, silyl or sulfonyl residue or a complexing agent.
- 7. The process of claim 6, wherein said complexing agent is a
- 2 compound of boric acid or phosphoric acid, or a compound containing a
- 3 covalently bonded metal.
- 8. The process of claim 7, wherein said metal is zinc, aluminum,
- 2 or copper.
- 9. A process for preparing compounds of claim 1, which comprises
- 2 converting the substructure

- 4 into another compound of claim 1
- 1 10. A process for inhibiting TNF $\alpha$  by administering to a patient in
- 2 need therefor an effective amount of the compound of claim 1.
- 1 11. A process for inhibiting TNF $\alpha$  by administering to a patient in
- 2 need therefor an effective amount of the compound of claim 4.
- 1 12. A process for inhibiting phosphodiesterase 4 by administering
- 2 to a patient in need therefor an effective amount of the compound of claim
- 3 1.

- 1 13. A process for inhibiting phosphodiesterase 4 by administering 2 to a patient in need therefor an effective amount of the compound of claim 3 4.
- 1 14. A process for treating an eosinophil-related condition by 2 administering to a patient in need therefor an effective amount of the 3 compound of claim 1.
- 1 15. A process for treating an eosinophil-related condition by 2 administering to a patient in need therefor an effective amount of the 3 compound of claim 4.
  - 16. A process for treating a chronic obstructive pulmonary disease, which comprises administering to a patient in need therefor an effective amount of a compound of claim 1.
- 1 17. A process for treating a chronic obstructive pulmonary disease,
  2 which comprises administering to a patient in need therefor an effective
  3 amount of a compound of claim 4.
- 18. A process for treating arthritis, rheumatoid arthritis,
  2 spondylitis, osteoarthritis, sepsis, septic shock, gram negative sepsis, toxic
  3 shock syndrome, respiratory distress syndrome, asthma, chronic pulmonary
  4 disorders, bone resorption diseases, transplant rejection reactions, autoimmune
  5 disorders, lupus erythematosus, multiple sclerosis, glomerulonephritis, uveitis,
  6 insulin dependent diabetes mellitus, chronic demyelinization, malaria,
  7 infection-related fever, infection-related myalgia, AIDS, cachexia, bronchial
- 8 asthma, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, eczema,
- 9 allergic angiitis, eosinophilic fasciitis, eosinophilic pneumonia, pulmonary

10	infilanceion with opin	iophilia, urticaria, ulcerative colitis, Crohn's disease,
11	psoriasis, keratosis, p	ulmonary neutrophilic infiltration, chronic obstructive
12	pulmonary disease, s	enile dementia, loss of memory, Parkinson's disease,
13	depression, stroke, ir	ntermittent claudication, benign prostate hyperplasia,
14	pollakuria, nycturia,	bladder atony, kidney stone colics, and analgesic
15	dependency, which c	omprises administering to a patient a pharmacologically
16	effective amount of	a compound of claim 1.

- 1 19. A pharmaceutical preparation which comprises a
  2 therapeutically effective amount of the compound of claim 1, together with
  3 one or more of a pharmaceutically acceptable carrier, diluent, and auxiliary
  4 ingredient.
  - 20. A process for preparing the pharmaceutical preparation of claim 12, which comprises preparing a pharmaceutically acceptable dosage form from a compound of claim 1, and from one or more of a pharmaceutically acceptable carrier, diluent, and auxiliary ingredient.